Résumé
Pharmacogenetic testing for clinical applications is steadily increasing. Correct and adequate use of pharmacogenetic tests is important to reduce unnecessary medical costs and adverse patient outcomes. This document contains recommended pharmacogenetic testing guidelines for clinical application, interpretation, and result reporting through a literature review and evidence-based expert opinions for the clinical pharmacogenetic testing covered by public medical insurance in Korea. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Sujets)
Anticoagulants/usage thérapeutique , Antidépresseurs/usage thérapeutique , Antimétabolites antinéoplasiques/usage thérapeutique , Antituberculeux/usage thérapeutique , Arylamine N-acetyltransferase/génétique , Maladie des artères coronaires/traitement médicamenteux , Cytochrome P-450 CYP2C19/génétique , Cytochrome P-450 CYP2C9/génétique , Cytochrome P-450 CYP2D6/génétique , Trouble dépressif/traitement médicamenteux , Génotype , Isoniazide/usage thérapeutique , Laboratoires hospitaliers/normes , Methyltransferases/génétique , Test pharmacogénomique/méthodes , Antiagrégants plaquettaires/usage thérapeutique , Embolie pulmonaire/traitement médicamenteux , Ticlopidine/analogues et dérivés , Tuberculose/traitement médicamenteux , Vitamin K epoxide reductases/génétique , Warfarine/usage thérapeutiqueRésumé
Pharmacogenetics is a rapidly evolving field, and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation and use of pharmacogenetic testing in clinical practice may result in an increase in medical costs and adverse patient outcomes. This document contains suggested pharmacogenetic testing guidelines for clinical application, interpretation, and reporting of the results through a literature review and evidence-based expert opinions. The clinical laboratory practice guideline includes clinical pharmacogenetic testing covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic testing are also addressed. This document aims to improve the utility of pharmacogenetic testing in routine clinical settings.
Sujets)
Humains , Expertise , Assurance , Corée , PharmacogénétiqueRésumé
Pharmacogenetics is a rapidly evolving field and the number of pharmacogenetic tests for clinical use is steadily increasing. However, incorrect or inadequate implementation of pharmacogenetic tests in clinical practice may result in a rise in medical costs and adverse outcomes in patients. This document suggests guidelines for the clinical application, interpretation, and reporting of pharmacogenetic test results based on a literature review and the collection of evidence-based expert opinions. The clinical laboratory practice guidelines encompass the clinical pharmacogenetic tests covered by public medical insurance in Korea. Technical, ethical, and regulatory issues related to clinical pharmacogenetic tests have also been addressed. In particular, this document comprises the following pharmacogenetic tests: CYP2C9 and VKORC1 for warfarin, CYP2C19 for clopidogrel, CYP2D6 for tricyclic antidepressants, codeine, tamoxifen, and atomoxetine, NAT2 for isoniazid, UGT1A1 for irinotecan, TPMT for thiopurines, EGFR for tyrosine kinase inhibitors, ERBB2 (HER2) for erb-b2 receptor tyrosine kinase 2-targeted therapy, and KRAS for anti-epidermal growth factor receptor drugs. These guidelines would help improve the usefulness of pharmacogenetic tests in routine clinical settings.